Tuesday, September 22, 2020
News
NEWS HOME
Ľ
PRESS RELEASES

Converge Biotech Announces the Launch of Vergiflu (Favipiravir 200 mg) in India to Treat Mild to Moderate Covid-19
  SocialTwist Tell-a-Friend  
   


Date: 04-08-2020 9:30AM
Source: Converge Biotech
Category: General, Consumer Interest, Social Issues, Healthcare & Biotechnology, Pharmaceutical, Retailers, Technology
Location: Hyderabad, India

Business Wire India

Arun Kumar Bijjala - Managing Director (Converge Biotech) with Vergiflu
Arun Kumar Bijjala - Managing Director (Converge Biotech) with Vergiflu

Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India. It will be marketed under the brand name VERGIFLUand is indicated for use in mild to moderate COVID-19 patients. Vergiflu is orally administered making it a convenient treatment option.

We are delighted to announce the launch of Vergiflu for treatment of mild to moderate COVID-19 patients. At a time when cases are witnessing an alarming trend, our accelerated launch is aimed towards offering patients in India a much needed and timely therapy option. This strengthens our portfolio and keeps our commitment of bringing affordable therapy, accessible to patients,” said Managing Director of Converge Biotech Pvt Ltd, Arun Kumar Bijjala.

Favipiravir is an off patent; broad spectrum oral anti-viral drug backed by strong clinical evidence and has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms. The drug is already approved for novel or re-emerging pandemic influenza virus infection in Japan since 2014, where high recovery rates have been reported with both 7 and 14 days of therapy in both mild and moderate patients. The drug has shorter viral clearance and faster recovery rate and is reported to have a wide therapeutic safety margin for COVID-19 dose.

The mechanism of action of Favipiravir is novel compared to existing influenza antivirals that primarily prevent entry and exit of the virus from cells. The drug has high affinity to RNA virus specific RNA polymerase and gets converted into an active phosphoribosylated form (favipiravir-RTP) in cells thereby inhibiting RNA polymerase activity.

The product is available from today in all major hospitals across the country. It will be sold only on prescription and the company will make sure that the drug is available to the patients.

Converge Biotech also has Prabinex HD (Injection vitamins c 1.5 g), Doxiverge (Inj Doxycycline 100 mg) and Oxihalt (Inj Glutathione 600mg) for hospitalised patients along with immunity boosters, Prabinex 500 mg (Tab Vitamin C 500mg) and Prabinex Z (Tab Vitamin C 500mg with Zinc 20mg); Divify (Vitamin D3 strips) and Tancyvit (Multivitamin).About CONVERGE BIOTECH

Converge Biotech is a leading healthcare company based at Hyderabad, having a nationwide presence. It has a strong foothold in the cardio-diabetic and critical care segment, with focus on providing high quality and affordable generic drugs to the patients. Converge Biotech aspires to become the CHANGE agents in the healthcare industry by providing breakthrough treatments with focus on quality, innovation and affordability. All products offered by the company are produced in WHO GMP certified facilities and are audited by dedicated quality and pharmacovigilance team to ensure compliance to stringent quality measures.

Converge Biotech was recognised as the fastest growing company in 2017. In the same year, the company also became ISO 9001:2008 certified, making it the youngest company to reach that milestone. The company received the prestigious Emerging Entrepreneur award in 2019. For more information on Converge Biotech, please visit https://convergebio.in/


More Press Releases

DSIJ Academy Adjudged the Best Stock Market Training Institute

Eatonís Twin Vortices Series Helps Hydrogen Fuel Cell Modules Operate at Peak Efficiency

Manage a Medical Emergency with an Online Personal Loan from Bajaj Finserv

HPE Completes Acquisition of SD-WAN Leader Silver Peak

Cube Highways Acquires Farakka-Raiganj Highways Limited

Coca-Cola India Aids the Rejuvenation of Sukkhad River in Alirajpur, Madhya Pradesh to Benefit Over 8,500 Lives

India Protein Score - New Report Identifies Indiaís Top Protein Rich Prepackaged Foods

Vernacular.ai Is Chosen to Be a Part of the World Economic Forumís Global Innovators Community

CGTN:†China Makes Proposals for UN's Role in Post-Pandemic Era

Changa App Set to Become One of the Top Short Video Platforms in India

Empathy in the Teamís Actions Has Given a New Meaning to the Companyís Work: Subodh

Singapore Government Extends National Digital Identity Programme With Face Verification Solution From iProov and Toppan Ecquaria

MeeamiTech Launches AI Based Noise Suppression for Windows, Android and iOS and Mac OS to Eliminate Background Noise from Voice and Video Calls

Hiranandani Signature Designated IFSC Offers Ready to Move in Commercial Spaces

After Securing Government Permissions on Drone Deliveries, Omnipresent Set to Disrupt Logistics in India

Adosphere Upskills 1.20 Lakh Gujarat Government Teachers Through Workplace from Facebook

Harbhajan Singh Launches Amulya Mica Imperial Premium Laminates Veneer Collection

PerkinElmer Launches Solus Listeria monocytogenes ELISA Assay for Testing Across Food and Environmental Samples

Matt Roney Named as Lumileds Chief Executive Officer

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Cong plans to put Scindia under pressure...
Kashi to be a model for development: Yog...
Opp to boycott Monsoon session if MPs' s...
Thane building crash death toll mounts t...
Farmers need many thousand markets, not ...
RS Dy Chairman to fast in protest of unr...
More...    
 
 Top Stories
Indian healthcare providers fast ad... 
Nitin Patel: Partial Rajkot hospita... 
Goa to revise home isolation protoc... 
NIA takes over Bengaluru violence p... 
98 Afghan civilians killed in past ... 
NTPC power plants to host industria... 
World record 20 crore people watche... 
This cancer drug can help in Covid-...